Reuters Market Eye - Credit Suisse upgrades Dr. Reddy's Laboratories(REDY.NS) to 'outperform' from 'neutral' and raises its target price to 2,150 rupees from 1,900 rupees, citing expectations for a strong pick up in U.S. sales in the coming quarters.
Credit Suisse also notes the market share for Dr. Reddy's Metoprolol drug, used for hypertension, is increasing.
Dr. Reddy's also expects upcoming approval of two limited competition products in the United States, Credit Suisse says after meeting with the drug maker's management.
Dr. Reddy's also expects fiscal 2015 growth in the United States to be stronger than fiscal 2014 due to some "significant" launches.
Trending On Reuters
Tata Motors shares fell more than 5 percent on Wednesday after a surprise drop in its bottom line, hit by weak demand for luxury Jaguars and Range Rovers in China, where automakers are under pressure to cut prices. Full Article
Factbox - China's leaders sign $80 bln of deals with India, Brazil and others Full Article